Bio-Techne Corporation
TECH
株式のランク
#1869
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
株価
$72.50
時価総額
$11.37B
変化（1日）
-0.10%
変化（1年）
17.20%
国
US
取引 Bio-Techne Corporation (TECH)
カテゴリー
Healthcare
Bio-Techne Corporation（TECH）のP/E比率
October 2026 時点のP/E比率 TTM 61.97
Bio-Techne Corporation の最新の財務報告および株価によると、現在の P/E (TTM) は 61.97 です。2024 年末時点での P/E は 67.18 でした。
Bio-Techne Corporation の P/E 比率の履歴（2000 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 61.97 | -43.88% |
| 2025 | 110.41 | 64.35% |
| 2024 | 67.18 | 49.36% |
| 2023 | 44.98 | -9.99% |
| 2022 | 49.97 | -59.78% |
| 2021 | 124.26 | 182.43% |
| 2020 | 44.00 | -46.54% |
| 2019 | 82.30 | 86.05% |
| 2018 | 44.24 | -22.03% |
| 2017 | 56.74 | 41.34% |
| 2016 | 40.14 | 18.38% |
| 2015 | 33.91 | 10.18% |
| 2014 | 30.78 | 34.96% |
| 2013 | 22.80 | -6.55% |
| 2012 | 24.40 | -11.39% |
| 2011 | 27.54 | 41.26% |
| 2010 | 19.49 | -14.94% |
| 2009 | 22.92 | -21.66% |
| 2008 | 29.25 | 10.46% |
| 2007 | 26.48 | -2.30% |
| 2006 | 27.11 | -3.27% |
| 2005 | 28.02 | -16.81% |
| 2004 | 33.69 | 21.76% |
| 2003 | 27.67 | -35.05% |
| 2002 | 42.59 | 7.61% |
| 2001 | 39.58 | -60.15% |
| 2000 | 99.34 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -53.55% |
US
|
|
| -28.36 | -145.76% |
US
|
|
| -24.57 | -139.65% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -51.05% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。